SCHEMBL164160

SCHEMBL164160

C#CC(O)(c1ccc(OC)cc1)c1ccc(OC)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ELANE P08246 1/20 0.46
CA1 P00915 3/20 0.46
CA2 P00918 3/20 0.46
CA12 O43570 1/20 0.46
CA7 P43166 1/20 0.46
CA9 Q16790 1/20 0.46
CA14 Q9ULX7 1/20 0.46
AOC3 Q16853 1/20 0.43
ALDH1A1 P00352 3/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
MAPT P10636 1/20 0.41
HSD11B1 P28845 1/20 0.40
LMNA P02545 1/20 0.40
ALOX15 P16050 1/20 0.40
APEX1 P27695 1/20 0.40
MAPK1 P28482 1/20 0.40
RECQL P46063 1/20 0.40
HSD17B10 Q99714 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
APP P05067 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25954061 1.00 ELANE (0.46) ELANECA1CA2CA12CA7
SCHEMBL25954134 0.94 ELANE (0.42) ELANECA1CA2CA12CA7
SCHEMBL25954108 0.94 LTA4H (0.48) ELANECA1CA2CA12CA7
SCHEMBL25954058 0.94 LTA4H (0.48) ELANECA1CA2CA12CA7
SCHEMBL25954105 0.94 ESR2 (0.48) ELANECA1CA2CA12CA7
SCHEMBL4568709 0.93 ACHE (0.54) ELANECA1CA2CA12CA7
SCHEMBL12206421 0.93 LTA4H (0.52) ELANECA1CA2CA12CA7
SCHEMBL1011203 0.93 KIF11 (0.45) ELANESMN1; SMN2LMNALTA4HCES2
SCHEMBL25954113 0.93 ELANE (0.45) ELANECA1CA2CA12CA7
SCHEMBL9042759 0.91 AHR (0.50) ELANEAOC3MAPTHSD11B1AHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 412 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-1999031096-A1 PIPERAZINE DERIVATIVES USEFUL AS HYPOGLYCEMIC AGENTS SHAMAN PHARMACEUTICALS, INC. (US) 1999-06-24 WO claimed
US-6444860-B1 None US disclosed
WO-2026047423-A1 COLOURED PHOTOCHROMIC COSMETIC INGREDIENT FOR COSMETIC COMPOSITIONS CHANGING COLOUR WHEN IRRADIATED WITH ULTRAVIOLET LIGHT, AND METHOD FOR THE PREPARATION THEREOF INTERCOS S.P.A. (IT) 2026-03-05 WO disclosed
US-12344617-B2 Indolonaphthopyrans TRANSITIONS OPTICAL, LTD. (IE) 2025-07-01 US disclosed
CN-113227098-B Indolonaphthopyrans 光学转变有限公司 2025-01-07 CN disclosed
CN-114031595-B Photochromic compound and application thereof 江苏视科新材料股份有限公司 2024-01-26 CN disclosed
EP-2545095-B1 METHODS FOR PRODUCING PHOTOSENSITIVE MICROPARTICLES, NON-AQUEOUS DISPERSIONS THEREOF AND ARTICLES PREPARED THEREWITH TRANSITIONS OPTICAL INC (US) 2024-01-24 EP disclosed
EP-4289831-A1 PHOTOCHROMIC COMPOUND, PHOTOCHROMIC COMPOSITION, PHOTOCHROMIC ARTICLE AND EYEGLASSES Hoya Lens Thailand Ltd. (TH) 2023-12-13 EP disclosed
WO-2023220461-A1 PHOTOINITIATORS, COMPOSITIONS, AND METHODS OF FORMING AN OBJECT QUADRATIC 3D, INC. (US) 2023-11-16 WO disclosed
US-20230359068-A1 OPTICAL ARTICLE, SPECTACLES, AND PHOTOCHROMIC COMPOUND HOYA LENS THAILAND LTD. (TH) 2023-11-09 US disclosed
US-5514817-A PHOTOCHROMIC PPG INDUSTRIES, INC. (US) 1996-05-07 US disclosed
WO-1996004576-A1 NOVEL SUBSTITUTED PHENANTHROPYRANS PPG INDUSTRIES, INC. (US) 1996-02-15 WO disclosed
EP-0691965-A1 PHOTOCHROMIC NAPHTHOPYRAN COMPOUNDS PILKINGTON PLC (GB) 1996-01-17 EP disclosed
US-5458814-A Ophthalmic lenses TRANSITIONS OPTICAL, INC. (US) 1995-10-17 US disclosed
WO-1995016215-A1 NOVEL SUBSTITUTED NAPHTHOPYRANS PPG INDUSTRIES, INC. (US) 1995-06-15 WO disclosed
US-5411679-A REVERSIBLE PHOTOCHROMIC COMPOUNDS TRANSITIONS OPTICAL, INC. (US) 1995-05-02 US disclosed
WO-1995005371-A1 PHOTOCHROMIC NAPHTHO(2,1-B)PYRANS PILKINGTON PLC (GB) 1995-02-23 WO disclosed
WO-1995005382-A1 PHOTOCHROMIC HETEROCYCLOCHROMENES PILKINGTON PLC (GB) 1995-02-23 WO disclosed
WO-1994022850-A1 PHOTOCHROMIC NAPHTHOPYRAN COMPOUNDS PILKINGTON PLC (GB) 1994-10-13 WO disclosed
WO-1994020869-A1 NOVEL BENZOPYRANS PPG INDUSTRIES, INC. (US) 1994-09-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12344617-B2 Indolonaphthopyrans TPH1, TPH2, IDO1 ELANE 4649/4885CA1 4619/4885CA2 4327/4885
US-20230359068-A1 OPTICAL ARTICLE, SPECTACLES, AND PHOTOCHROMIC COMPOUND GRK1, TCOF1, ARPC1B ELANE 4567/4885CA1 1898/4885CA2 816/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.